Clinical Trials Logo

HPV Vaccine clinical trials

View clinical trials related to HPV Vaccine.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05291871 Active, not recruiting - HPV Infection Clinical Trials

Immunogenicity of Fractional Dose of the HPV Vaccines

Start date: June 15, 2022
Phase: Phase 4
Study type: Interventional

This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and 12 months

NCT ID: NCT04982614 Active, not recruiting - Hiv Clinical Trials

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Start date: April 1, 2022
Phase: Phase 4
Study type: Interventional

This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a population of children, adolescents and young women living with HIV in Eswatini. This protocol seeks to assess immunogenicity of a two-dose 9vHPV vaccine regimen among girls and boys (9-14 years) and young women (15-26 years) living with HIV on antiretroviral therapy versus a three-dose 9vHPV vaccine regimen among HIV uninfected young women (15-26 years) in Eswatini. The secondary objectives include examining the safety profiles of the two-dose 9vHPV regimen in those living with HIV and the three-dose 9vHPV regimen in HIV-uninfected young women, as well as measuring the completion of the vaccination series among those living with HIV and those who are not infected with HIV.

NCT ID: NCT04235257 Active, not recruiting - HPV Infection Clinical Trials

Intradermal, Fractional Dose of HPV Vaccines:

Start date: November 1, 2020
Phase: Phase 4
Study type: Interventional

This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months, and 24 months.